Reliance Global Group (EZRA) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
26 Dec, 2025Executive summary
2024 saw continued revenue growth and improved operational performance, driven by disciplined fiscal management, technology investments, and targeted acquisitions.
The One Firm strategy unified agency operations into a technology-driven platform, boosting efficiency and reducing costs.
Expansion of the AI-powered quote-and-bind platform and the pending Spetner Associates acquisition are expected to drive further value and scalable growth in the InsurTech sector.
Financial highlights
Revenue increased by 2% year-over-year to $14.1 million for 2024, reflecting sustained organic growth.
Net loss decreased by 24% to $9.07 million, aided by fewer intangible impairment charges and balance sheet streamlining.
Adjusted EBITDA loss improved by 39% to $(321,224), showing progress toward profitability.
Salaries and wages decreased by 4% to $7.23 million, while general and administrative expenses increased by 3% to $4.22 million, partly due to acquisition costs and inflation.
Commission expense rose by 12% to $4.19 million, reflecting changes in revenue mix and organic growth.
Outlook and guidance
Management anticipates significant growth driven by the Spetner Associates acquisition, continued platform enhancements, and disciplined expansion.
Ongoing enhancements to the AI-powered quote-and-bind platform are expected to drive further value.
Focus remains on innovation, operational excellence, and leveraging technology for scalable, long-term growth.
Latest events from Reliance Global Group
- Net loss improved to $1.4M as insurance growth and tech/life sciences investments advanced.EZRA
Q1 20268 May 2026 - All proposals passed, with leadership focused on growth and stockholder value.EZRA
AGM 20266 May 2026 - Strategic tech expansion, divestitures, and improved financials position for future growth.EZRA
Q4 20256 May 2026 - Strategic investment in Innervate Radiopharmaceuticals advances late-stage healthcare platform exposure.EZRA
Proxy filing4 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and major share issuance.EZRA
Proxy filing23 Mar 2026 - Shareholders will vote on director elections, equity plan expansion, and a $50M share issuance.EZRA
Proxy Filing12 Mar 2026 - Q2 net loss improved 62%, Spetner deal to double revenue and boost profitability.EZRA
Q2 20242 Feb 2026 - Raising $5.3M for growth, tech, and digital assets amid dilution and Nasdaq compliance risks.EZRA
Registration Filing23 Jan 2026 - Q3 2024 delivered revenue growth, cost cuts, positive Adjusted EBITDA, and major M&A and tech moves.EZRA
Q3 202415 Jan 2026